Bio-Techne Corporation TECH
At closeNov 11, 2026, 4:28 PM EST
After hours · Nov 11, 4:28 PM ET
- YTD
- +23.79%
- 1 year
- +23.01%
- Market cap
- 11.44B
- Revenue (ttm)
- 1.23B
- Profit margin
- 14.00%
- EPS (ttm)
- 1.09
- Shares out
- 157.09M
- P/E ratio
- 66.79
- Forward P/E
- 31.48
- Dividend
- 0.32 (0.44%)
- Ex-dividend date
- Nov 12, 2026
- YTD return
- +23.79%
- 1-year return
- +23.01%
- Volume
- 2.61M
- Avg volume
- 2.82M
- Open
- 72.83
- Previous close
- 72.82
- Day's range
- 72.73 – 72.83
- 52-week range
- 43.20 – 72.88
- Beta
- 1.27
- Analysts
- Hold
- Price target
- 70.50 (-3.2%)
- Earnings date
- Feb 2, 2027
5D +0.01 (+0.01%)
Key statistics
- Enterprise value
- 11.37B
- PEG ratio
- 2.18
- Price / sales
- 9.31
- Price / book
- 5.28
- Dividend yield
- 0.44%
- Payout ratio
- 29.36%
- Revenue growth
- 4.60%
- Free cash flow
- 277.76M
- Total cash
- 351.13M
- Total debt
- 285.56M
- Return on equity
- 8.33%
- Short % of float
- 4.92%
- 50-day average
- 72.50
- 200-day average
- 63.28
Analyst view
Consensus: hold
- Target (low)
- 50.00
- Target (mean)
- 70.50
- Target (high)
- 73.00
- Strong buy0
- Buy0
- Hold12
- Sell1
- Strong sell0
Next earnings
Feb 2, 2027
Expected Feb 2, 2027. Consensus EPS estimate 0.48261.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 2, 2027 | Dec 30, 2026 | 0.465 | — | — | — |
| Nov 6, 2026 | Sep 30, 2026 | 0.44 | 0.44 | 0.00 | 0.00% |
| Aug 12, 2026 | Jun 30, 2026 | 0.519 | 0.52 | 0.00 | +0.19% |
| May 6, 2026 | Mar 31, 2026 | 0.55 | 0.53 | -0.02 | -3.64% |
| Feb 4, 2026 | Dec 31, 2025 | 0.43 | 0.46 | +0.03 | +6.98% |
| Nov 5, 2025 | Sep 30, 2025 | 0.4214 | 0.42 | 0.00 | -0.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 2026 | Wells Fargo | down | Overweight | Equal-Weight |
| Jul 9, 2026 | RBC Capital | down | Outperform | Sector Perform |
| Jun 30, 2026 | TD Cowen | down | Buy | Hold |
| Jun 30, 2026 | Benchmark | down | Buy | Hold |
| Jun 29, 2026 | Citigroup | down | Buy | Neutral |
| Jun 26, 2026 | Stephens & Co. | down | Overweight | Equal-Weight |
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bio-techne.com
News
Stock Market: Will S&P 500 Open Up or Down Today?
TECH Q1 Earnings & Revenues Beat, Merck KGaA Merger Deal Advances Bio-Techne Opens New Bristol Facility
Bio-Techne Receives Shareholders' Approval For Proposed Acquisition By Merck KGaA
Bio-Techne Announces SBTi Validation Of 70% Scope 1 & 2 Emissions Reduction Target By FY2031 And Supplier Engagement Commitment, Reporting Significant Operational Emissions Cuts In FY2026
Wells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73
Bio-Techne Q4 Adj. EPS $0.52, Inline, Sales $321.191M Beat $314.679M Estimate
Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover RBC Capital Downgrades Bio-Techne to Sector Perform, Raises Price Target to $73
TD Cowen Downgrades Bio-Techne to Hold, Raises Price Target to $73
Your note
Sign in to keep a note on TECH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAUMGARTNER ROBERT V | Director | Stock Award(Grant) | Oct 28, 2026 | 59,634 |
| BUSHMAN JULIE L. | Director | Stock Award(Grant) | Oct 28, 2026 | 11,525 |
| GEIST WILLIAM | Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 24,943 |
| HIGGINS JOHN L | Director | Stock Award(Grant) | Oct 28, 2026 | 80,004 |
| HIPPEL JAMES | Chief Financial Officer | Conversion of Exercise of derivative security | Oct 29, 2026 | 176,720 |
| KEEGAN JOSEPH D | Director | Stock Award(Grant) | Oct 28, 2026 | 18,161 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.93% | 14,025,816 | 1.02B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.50% | 10,218,558 | 743.91M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 4.67% | 7,343,324 | 534.59M | Jun 29, 2026 |
| HBK Investments L P | 4.34% | 6,825,000 | 496.86M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.14% | 6,506,360 | 473.66M | Jun 29, 2026 |
| Morgan Stanley | 4.06% | 6,374,717 | 464.08M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.16% | 4,968,867 | 361.73M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.58% | 4,056,808 | 295.34M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 3,586,562 | 261.10M | Jun 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P 500 Equal Weight ETF | 1.72% | 2,707,457 | 197.10M | Sep 29, 2026 |
| Eaton Vance Growth Trust-Eaton Vance Atlanta Capital SMID-Cap Fund | 1.66% | 2,604,519 | 189.61M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 2,089,474 | 152.11M | Sep 29, 2026 |
